BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the Company) has announced the pricing of US$650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the notes) in a private offering (the offering) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The offering was upsized from the previously announced offering of US$400 million aggregate principal amount of notes. In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional US$97.5 million aggregate principal amount of notes. The sale of the notes is expected to close on January 28, 2021, subject to customary closing conditions.
Latham & Watkins LLP represents the initial purchasers in the offering with a corporate deal team led by New York partner Marc Jaffe and Bay Area partners Brian Cuneo and Phillip Stoup, with Los Angeles associate Jennifer Pesce. New York partners Greg Rodgers and Reza Mojtabaee-Zamani advised on convertible debt matters, with New York associates Jack Neff and Ariel Robbins-Rothman. Advice was also provided on tax matters by New York partner Bora Bozkurt, with associate Ronald Moore; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associates Nathan Beaton and Lacey Henry; and on intellectual property matters by Bay Area/San Diego partner Chris Hazuka, with San Diego associate Robert Yeh.